Sun Pharmaceutical Industries Ltd.’s partnered novel topical anti-acne treatment Winlevi (clascoterone cream 1%) generated a fair share of discussion at the company’s fiscal second-quarter earnings call, with the firm’s senior management outlining early initiatives to covert initial physician interest into "repeated" prescriptions.
Sun’s CEO (North America) Abhay Gandhi said Winlevi, which represents a new class of topical medication in dermatology, will complement the firm’s existing oral acne portfolio, strengthening its position in
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?